Ocular Inflammation and Pain Market & Epidemiology Outlook 2025-2034 Featuring Analysis of DEXTENZA, BYQLOVI and OCS-01 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ocular Inflammation and Pain - Market Insights, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

This report examines the landscape, offering detailed epidemiological data and patient demographics across major markets from 2020 to 2034.

It highlights current treatment trends, unmet medical needs, and market potential, enabling stakeholders to make informed strategic decisions. The report covers diagnosis and treatment algorithms, focusing on symptom relief and prevention, with protocols for corticosteroid and NSAID therapies.

Epidemiology insights reveal trends and assumptions, presenting data with clarity to understand disease impact. Key secondary findings indicate higher prevalence among females, particularly in conditions like uveitis.

Key Highlights

• The study of ocular inflammation and pain is vital as these conditions may stem from an array of processes, manifesting as discomfort around the eyes. The market is poised for steady growth fueled by the prevalence of ocular disorders and advancements in diagnostics.
• Innovative therapies like DEXTENZA and BYQLOVI represent the move towards long-acting, targeted treatments.
• Harrow has acquired exclusive US rights to BYQLOVI, expected in Q4 2025, as the first new ophthalmic steroid in over 15 years.
• Oculis's OCS-01 is under development as a once-daily topical solution delivering sustained anti-inflammatory effects.
• Market growth is driven by effective therapies and innovative delivery systems. Issues like recurrence drive demand for durable solutions, with emerging sustained-release options aiming to improve outcomes.

Ocular Inflammation and Pain Market Outlook

An increase in the ocular inflammation and pain market is anticipated, driven by population prevalence and advancements in therapeutic options. Continuous innovation is expected to improve treatment efficacy, fueling market dynamics significantly by 2034.

Marketed Ocular Inflammation and Pain Drugs

Key products include DEXTENZA by Ocular Therapeutix and BYQLOVI by Formosa Pharmaceuticals, with emerging candidates like OCS-01 by Oculis continuing to advance the market.

Ocular Inflammation and Pain Drug Chapters

Market segmentation research details country-specific market sizes, therapeutic uptake, and competitive positioning for both current and emerging therapies.

Competitive Intelligence Analysis

Our analysis uncovers market dynamics and competitive positioning, employing tools like SWOT analysis. This helps stakeholders understand pipeline developments and strategic trends.

Key Findings

• Females have a higher stake in neuropathic ocular pain incidence.
• Uveitis shows a variable incidence across demographics and regions.
• The forecast anticipates an evolving landscape for therapies from 2025 to 2034.

Key Topics Covered

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

3.1. Market Share (%) Distribution by Therapies in 2024

3.2. Market Share (%) Distribution by Therapies in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Types

7.3. Causes

7.4. Pathophysiology

7.5. Symptoms

7.6. Risk Factor

7.7. Diagnosis

7.7.1. Diagnostic Algorithm

7.7.2. Diagnostic Guidelines

7.8. Treatment and Management

7.8.1. Treatment Algorithm

7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale: The 7MM

8.3. Total Prevalent Cases of Ocular Inflammation and Pain in the 7MM

8.4. Total Diagnosed Prevalent Cases of Ocular Inflammation and Pain in the 7MM

8.5. The US

8.6. EU4 and the UK

8.7. Japan

9. Patient Journey

10. Marketed Therapies

10.1. Key Cross Competition

10.2. DEXTENZA (dexamethasone ophthalmic insert): Ocular Therapeutix

10.3. BYQLOVI (Clobetasol Propionate Ophthalmic Suspension): Formosa Pharmaceuticals

11. Emerging Therapies

11.1. Key Cross Competition

11.2. OCS-01: Oculis

12. Ocular Inflammation and Pain: Seven Major Market Analysis

12.1. Key Findings

12.2. Key Market Forecast Assumptions

12.3. Market Outlook

12.4. Attribute Analysis

12.5. Total Market Size of Ocular Inflammation and Pain in the 7MM

12.6. Market Size of Ocular Inflammation and Pain by Therapies in the 7MM

12.7. The US Market Size

12.8. EU4 and the UK Market Size

12.9. Japan Market Size

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Ocular Inflammation and Pain Market Access and Reimbursement

16.1. United States

16.2. EU4 and the UK

16.3. Japan

For more information about this report visit https://www.researchandmarkets.com/r/pr28dr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.